Tian Xiangguo, Shi Yongjun, Hu Jinhua, Wang Guangchuan, Zhang Chunqing
Department of Gastroenterology, Provincial Hospital Affiliated to Shandong University, 324 Jingwu Weiqi Road, Jinan, Shandong, 250021, People's Republic of China.
Hepatol Int. 2013 Jun;7(2):636-44. doi: 10.1007/s12072-013-9433-4. Epub 2013 Mar 13.
To compare the long-term results of modified percutaneous transhepatic variceal embolization with cyanoacrylate (PTVE) and the transjugular intrahepatic portal systemic shunt (TIPS) for treating esophageal variceal bleeding.
Patients with cirrhosis and variceal bleeding who underwent TIPS and PTVE with cyanoacrylate between January 2006 and December 2010 were selected. We performed chart reviews to determine the rebleeding rate, survival and the rate of encephalopathy.
This retrospective study included 96 PTVE patients and 43 TIPS patients, with a median follow-up of 30.4 and 31.6 months in the two groups, respectively. Rebleeding occurred in 13 patients (30.2 %) in the TIPS group and in 20 patients (20.8 %) in the PTVE group (p = 0.229). For patients with model for end-stage liver disease (MELD) scores >18 at 1, 3 and 5 years, the survival rates were 84.2, 39.9 and 16.0 %, respectively, in the TIPS group, and they were 96.7, 72.0 and 36.0 %, respectively, in the PTVE group (p = 0.037). Sixteen (16.7 %) PTVE patients and 25 (58.1 %) TIPS patients developed encephalopathy (p = 0.000). Mean MELD and Child-Pugh scores improved significantly in modified PTVE patients. However, no such changes were observed in TIPS patients.
PTVE and TIPS were comparable in terms of variceal rebleeding prevention. However, in >18-MELD-score patients, PTVE offered better survival than TIPS. In addition, PTVE offered lower incidence of encephalopathy than TIPS.
比较改良经皮经肝静脉曲张氰基丙烯酸酯栓塞术(PTVE)和经颈静脉肝内门体分流术(TIPS)治疗食管静脉曲张出血的长期疗效。
选取2006年1月至2010年12月期间接受TIPS和氰基丙烯酸酯PTVE治疗的肝硬化和静脉曲张出血患者。我们进行病历回顾以确定再出血率、生存率和肝性脑病发生率。
这项回顾性研究纳入了96例PTVE患者和43例TIPS患者,两组的中位随访时间分别为30.4个月和31.6个月。TIPS组有13例患者(30.2%)发生再出血,PTVE组有20例患者(20.8%)发生再出血(p = 0.229)。对于终末期肝病模型(MELD)评分>18的患者,在1年、3年和5年时,TIPS组的生存率分别为84.2%、39.9%和16.0%,PTVE组分别为96.7%、72.0%和36.0%(p = 0.037)。16例(16.7%)PTVE患者和25例(58.1%)TIPS患者发生肝性脑病(p = 0.000)。改良PTVE患者的平均MELD和Child-Pugh评分显著改善。然而,TIPS患者未观察到此类变化。
在预防静脉曲张再出血方面,PTVE和TIPS具有可比性。然而,对于MELD评分>18的患者,PTVE的生存率优于TIPS。此外,PTVE的肝性脑病发生率低于TIPS。